2011年4月13-16日,化学与药物结构分析领域内享有极高声誉的国际性会议——CPSA将再次于中国上海召开。一年一度的CPSA起始于1998年,已经连续举办了十三届,本界会议的主题是“改变药物研发模式:东西方的交遇。”
“CPSA上海2011”是一个为科学家们提供共同、平等交流的场所和平台,所有报告内容都将是报告人的切身经历和经验,内容涉及多个方面,包括:政策法规、ADME和生物分析、药物相互作用和药物遗传学、药物研发中的PK/PD、药学/分析科学、外包策略探讨、新型给药技术、药物研发中的生物标记、生物制品发展、生物分析技术等。
会议同期活动还包括:短期培训、研讨班、专题讨论会、墙报、展览等。此次会议欢迎投递论文,2011年3月15日之前请把论文题目、作者、摘要发送到info@milestonedevelopment.com,字数控制在250字以内。另外,会议还设置了青年科学家奖,请于2011年3月15日前将申请表、摘要发送至wenfang.miao@pharmaron.com及ziqiang.z.cheng@gsk.com,主办方将为获奖者颁发现金奖励及获奖证书。
会议具体日程现公布如下:
Wednesday, April 13 - Workshops
Workshops
1:00 pm - 5:00 pm
Biotransformation: Lead Optimization and Clinical Candidate Selection
Through in Vitro ADME Evaluation
Workshop Leader: Mingshe Zhu, Bristol-Myers Squibb
Common in Vitro ADME Assays: Methods and Data Interpretation
Weiqing Chen, ChemPartner
Assessment of Transporter-Mediated Drug-Drug Interactions:
Current Strategy and Methodology
Cindy Xia, Millennium
Drug Metabolite Identification in Drug Discovery Using High-Resolution
Mass Spectrometry
Jie Xing, University of Shandong, China
Design Proper in Vitro ADME Studies to Meet Needs in Drug Discovery
Mingshe Zhu, Bristol-Myers Squibb
1:00 pm - 5:00 pm
Bioanalysis: LC-MS/MS Bioanalysis from Drug Discovery to Development:
Processes, Technologies and Regulations
Workshop Leader: Jian Wang, Bristol-Myers Squibb
Overview of LC-MS/MS Bioanalysis in Pharmaceutical Industry:
Processes and Applications
Danlin Wu, Roche
Technical Fundamentals in LC-MS/MS Bioanlytical Method Development,
Validation and Sample Analysis: Procedures, Issues and Solutions
Yuan-Qing Xia, Bristol-Myers Squibb
Performing Regulated Bioanalysis, Challenges and Case Studies from
a CRO Perspective
Xiaohang Shen, WuXi AppTec
Discovery Bioanalysis
Jian Wang, Bristol-Myers Squibb
1:00 pm - 5:00 pm
Pharmaceutical Analysis
Workshop Leaders: Gang Xue, Pfizer; Yong-Guo “Fred” Li, Roche
High Speed and High Efficiency Method Development
Gang Xue, Pfizer
ICH Q-Series, Key Points Exploration
Yong-Guo “Fred” Li, Roche
Dissolution Design and Testing, Critical for Oral Drug
Mufeng Xie, Shanghai Institute for Food and Drug Control (SIFDC))
Evening
Sponsor’s Dinner
Hosted by Thermo Fisher Scientific
Introduction and Welcome
Iain Mylchreest, Vice President and General Manager, Thermo Fisher Scientific
Applying Proven Proteomic Workflows and Tools for Quantitative Bioanalysis of
Large Molecules
Jonathan McNally, Marketing Manager for Bioanalysis, Thermo Fisher Scientific
Thursday, April 14 - Main Symposium
8:15 am – 8:30 am
Welcome
Mike Lee, Milestone Development Services
Ballroom 1-2
8:30 am - 8:45 am
Meeting Overview
Jing-Tao Wu, Millennium Pharmaceuticals
Ballroom 1-2
8:45 am – 9:30 am
Plenary Lecture
Challenges and Future Direction of Oncology Drug Development
Pete Smith, Senior Vice President, Millennium Pharmaceuticals
Ballroom 1-2
10:15 am - 11:45 am
Parallel Sessions
Parallel Track I ADME I
Ballroom 1
10:15 am - 11:45 am
Comparison of Regulatory Requirements on DMPK Package Chair: Jeff Zhang, Novartis
Overview of DMPK Package in China: Regulatory Requirement & Current Practice
Dafang Zhong, Shanghai Institute of Materia Medica
US/Europe Regulatory Requirements on Metabolites in Safety Testing
Mingshe Zhu, Bristol-Myers Squibb
US/Europe Regulatory Requirements on Drug/Drug Interactions
Mark Milton, Novartis
Parallel Track II Pharmaceutical Sciences
Rhine Ballroom
10:15 am - 11:45 am
Emerging Trends and Technologies in Pharmaceutical Sciences
Chair: Jack Chen, DSM
PAT Applications in a Quality-by-Design (QbD) Environment
Kevin Bittorf, Vertex Pharmaceuticals
Enhancing Product Performance Through Innovative Formulation and Manufacturing
Qun Lu, Merck
New Technology in Polymorph Studies
Beth Sarsfield, Bristol-Myers Squibb
Parallel Track III Bioanalytical
Ballroom 2
10:15 am - 11:45 am
Dried Blood Spots and Other Emerging Bioanalytical Technologies Chair: Naidong Weng, Johnson & Johnson
Applications of DBS for Clinical Bioanalysis Support
Tom Verhaeghe, Johnson & Johnson
Case Study of Dried Blood Spots Application in Toxicology Study
Luke Bi, Covance
High Resolution Accurate Mass Spectrometry in Quantitative Bioanalysis: Effect of
Mass Resolution and Extraction Window on Selectivity
Yuan-Qing Xia, Bristol-Myers Squibb
High-Throughput Bioanalysis Using an Ultra-fast On-line Extraction System
Wenying Jian, Johnson & Johnson
11:45 am - 1:15 pm Lunch & Roundtable Discussion
11:45 pm - 1:15 pm Sponsored Roundtable Workshops
Hosted by AB Sciex - Danube Ballroom
High Resolution Quantitation for Bioanalysis using AB Sciex 5600 Triple Tof
Hesham Ghobarah, AB Sciex
Targeted Peptide Quantitation using MIDAS Workflow
Wenhai Jin, AB Sciex
Hosted by McKinley Scientific - The Boardroom
Topic to be announced
1:15 pm – 5:00 pm
Parallel Sessions
Parallel Track I ADME II
Ballroom 1
1:15 pm - 2:45 pm
Drug-Drug Interactions
Chairs: Cindy Xia, Millennium; Angela Wong, Merck Serono
DDI of Herbal Medicines
Chuan Li, Shanghai Institute of Materia Medica
Transporter-mediated DDI
Cindy Xia, Millennium Pharmaceuticals
Pharmacogenetics in Drug Discovery and Development
Renke Dai, South China University of Technology
3:00 pm - 5:00 pm
ADME Optimization to Advance CNS and Oncology Drug Discovery & Development:
Industry Case Studies
Chairs: Zack Cheng, GlaxoSmithKline; Haojing Rong, Pfizer
Blood-Brain Barrier Transporters:
Friend or Enemy for CNS Drug Discovery and Development?
Zack Cheng, GlaxoSmithKline
Intranasal Administration for CNS Drug Delivery: Hope or Hype?
Haojing Rong, Pfizer
ADME Support of Oncology Programs:
Risk Management vs. Pursuit of Appropriate Drug-Like Properties
Hongjian Zhang, PharmaResources
Predictive Toxicology Approaches for Small Molecule Oncology Drugs
Vic Kadambi, Millennium Pharmaceuticals
Parallel Track II Pharmaceutical Analysis Summit
Ballroom 2
1:15 pm – 2:45 pm
High-speed, High-Resolution Techniques for Pharmaceutical Analysis
Chairs: Anne-Françoise Aubry, Bristol-Myers Squibb; Xiaoyi Gong, Merck
Chromatographic Methodology and Technology for Developing TCM
Xinmiao Liang, Dalian Institute of Chemical Physics
Mass Spectrometry and Ion Mobility-Based Techniques for Rapid Pharmaceutical
Analysis: No Sample Preparation?
Zhongli Zhang, Pfizer
Evaluation of Ionic Liquid Stationary Phases for GC-MS and GCxGC Analyses of
Fatty Acids in Marine Biota
Qun Gu, Dalian Institute of Chemical Physics
3:00 pm - 5:00 pm
Analytical Approaches for the Determination of Low-Level Impurities to Comply
with International Regulations
Chairs: Todd Gillespie, Eli Lilly and Company; Roman Szucs, Pfizer
Genotoxic Impurities in Drug Development
James An, Wilmington Pharmatech
Analytical Strategy for Quantifying Low-Level Genotoxic Impurities
Todd Gillespie, Eli Lilly and Company
Quantitation of API Impurities Near the Qualification Level
Tianmin Zhu, Hisun Pharmaceuticals
High-throughput Chiral Analyses
Xiaoyi Gong, Merck
Parallel Track III Workshop
Rhine Ballroom
1:15 pm - 5:00 pm
Absolute Quantification of Peptides and Proteins: From Sample Preparation and
Chromatography to ESI-MS/MS
Leaders: Gary Valaskovic, New Objective; Nalini Sadagopan, Agilent Technologies
5:00 pm - 6:00 pm
Poster Viewing - Yangtze Ballroom
6:00 pm - 9:00 pm
Dinner
Ballroom 1-2
Welcome Toast - Agilent Technologies
Keynote Lectures
Stable and Reactive Metabolites in Drug Research
Scott Obach, Pfizer
Simultaneous Determination of the PK profile of Clozapine and its Metabolites in
Rat Plasma Using a High-Resolution 6540 QTOF instrument
Lester C. Taylor, Shane Tichy, and Na Pi, Agilent Technologies
Friday, April 15
8:15 am – 9:00 am
Plenary Lecture
Ballroom 1-2
Multi-dimensional Chromatography-Mass Spectrometry for Protein Analysis
Xiangmin Zhang, Fudan University
9:30 am - 11:00 am
Parallel Sessions
Parallel Track I Novel Drug Delivery Technologies
9:30 am - 11:00 am
Chair: Mark Milton, Novartis
Ballroom 1
Antibody Drug Conjugates - A General Review
Mark Milton, Novartis
Drug Targeting and Nanotechnology
Yiqiao Hu, Nanjing University
Novel Technologies for the Delivery of Biologics
Zhixuan Wang, Novartis
Parallel Track II Biomarker Discovery
9:30 am - 11:00 am
Chairs: Scott Fountain, Pfizer; Nalini Sadagopan, Agilent
Ballroom 2
Application of Target and Mechanism Biomarkers in Advancing Biotherapeutics
and Pharmatherapeutics
Scott Fountain, Pfizer
Implementing Biomarkers into Clinical Trials on a Global Scale
Tom Turi and LiBin Ma, Covance
Proteomics Approaches to the Development of Plasma Markers for Predicting Pre-
Term Birth
Kevin P. Rosenblatt, The Brown Foundation Institute of Molecular Medicine
Parallel Track III Comparison of Regulations for Pharmaceutical Sciences
9:30 am - 11:00 am
Chair: Gang Xue, Pfizer
Rhine Ballroom
Reviews of CMC Requirements for Drug Development, Registration and Post
Approval
Yanyun Chen, Pfizer
CMC Requirements for Analytical/QC
Wenfang Miao, Pharmaron
11:00 am - 12:00 pm
Poster Session - Yangtze Ballroom
12:00 pm - 1:30 pm
Lunch / Roundtable Discussion
12:30 pm - 1:30 pm
Sponsored Roundtable Workshops
Hosted by Thermo Fisher Scientific - Danube Ballroo
Identification and Screening for Drug Impurities, Leachables, and Extractables
Using New Software and High Resolution Mass Spectrometery
Kate Comstock, Marketing Specialist for Drug Metabolism, Thermo Fisher Scientific
Hosted by New Objective - Boardroom
Topic to be announced
Gary Valaskovic, New Objective
1:30 pm – 5:00 pm
Parallel Sessions
Parallel Track I ADME III
Ballroom 1
1:30 am – 3:30 pm
Development of Biologics as Therapeutics Chair: Lawrence Gan, Biogen Idec; Haijing Rong, Pfizer
Introduction of Biologics
Jennifer Visich, Genentech
Biologics Drug Drug Interaction
Lewis Klunk, Biogen Idec
PK/PD of Biologics
Anup Zutshi, Pfizer
3:45 pm - 5:15 pm
PK/PD in Drug Discovery & Development Chairs: Jenny Zheng, Pfizer; Zhuohan Hu, Research Institute for Liver Diseases
The Myths of PK/PD - Empirical? Mechanistic? Or System?
Jenny Zheng, Pfizer
A Mechanistic-Based PK/PD Modeling for Drug Metabolism by CYP3A in Rat
Wei Lu, Peking University, China
Case History – Use of PK/PD in Drug Candidate Selections
Lawrence Gan, Biogen Idec
Application of PBPK and In-Vitro Hepatocyte Models to
Accurately Predict Human PK
Yurong Lai, Pfizer
Parallel Track II Regulated Bioanalysis Summit
Ballroom 2
1:30 pm - 3:30 pm
Regulated Bioanalysis: State of the Art Chair: Danlin Wu, Roche
Perspectives on Regional Differences in Bioanalytical Regulations
Mark Arnold, Bristol-Myers Squibb
Strategies to Avoid Pitfalls in Developing and Validating High-quality Quantitative
Bioanalytical Methods to Support Regulated Studies
Eric Yang, GlaxoSmithKline
Importance of Reagent Quality for Ligand Binding Assay Development
Roland Staak, Roche
Validation and Application of Ligand Binding Assays for Protein Therapeutics
Quantitation and Immunogenicity Testing: A GLP Bioanalytical Lab Perspective
Eginhard Schick, Roche
3:45 pm – 5:15 pm
Regulated Bioanalysis: Current Challenges
Chair: Anne Françoise-Aubry, Bristol-Myers Squibb
Unexpected Event Investigations in the Bioanalytical Laboratory
Anne Françoise-Aubry, Bristol-Myers Squibb
Bioanalytical Method Transfer: Challenges & Opportunities
Naidong Weng, Johnson & Johnson
Harmonization of Regulated Bioanalytical Operation at both U.S. and China Sites
XinPing Fang, XenoBiotic Laboratories
Parallel Track III Workshop
Rhine Ballroom
1:30 pm - 5:15 pm
Pharmacokinetic Applications in Drug Discovery and Development: Human PK and
Efficacious Dose Prediction
Workshop Leaders: Frances Wang, Astra Zeneca; Xingmei Han, Novartis
6:00 pm - 9:30 pm
CPSA Shanghai Gala Dinner
Ballroom 1-2
Held in conjunction with local bioanalytical and metabolism discussion groups
6:00 pm - 7:00 pm
Dinner Gala
7:00 pm - 7:30 pm
Awards and Announcements
7:30 pm - 9:30 pm
Point/Counterpoint Discussions
Future Direction of Pharmaceutical R&D in China
Moderator: Jeff Zhang, Novartis
Saturday, April 16
Morning
Joint session with local bioanalytical and metabolism discussion groups
Application of PK/PD in Drug Discovery and Development
Li Yu, Hoffmann-La Roche
Application of In-Vitro Data to Predict Clinical PK and Drug-Drug Interaction
by Simcyp
Jing Lin, Pfizer
Application of Radioisotopes in Drug Absorption, Distribution, Metabolism,
and Excretion Studies
Zhe-ming Gu, XBL-China
1、会议注册
下载 CPSA上海2011参会注册表.pdf,填写完毕后通过邮件、传真或邮寄形式发至主办方。会议注册费用说明如下:
|
2011-1-22之前 |
2011-1-23 至2011-3-30 |
2011-3-30之后 |
注册费 |
$180 |
$200 |
$300 |
学生/博士后注册费 |
$80 |
$100 |
$150 |
研讨班注册费 |
$50 |
$60 |
$75 |
付款方式:
信用卡:American Express, Master Card, Visa
电汇:请联系 info@milestonedevelopment.com
支票:Milestone Development Services (US bank收)
中国参会者请联系冯军豪先生
电话:021-69189215/52179515
传真:021-69189215
Email:frank.fung@mice-partners.com
2、住宿
本次会议将在上海浦东淳大万丽酒店举办,如您计划入住该酒店,2011年3月15日之前预定房间有优惠。
3、会议论文的提交
2011年3月15日之前请把论文题目、作者、摘要发送到info@milestonedevelopment.com,字数控制在250字以内。
4、青年科学家奖
请于2011年3月15日前将申请表、摘要发送至wenfang.miao@pharmaron.com和ziqiang.z.cheng@gsk.com。主办方将为获奖者颁发现金奖励及获奖证书。
5、会议日程
2011年4月13日,星期三 短期培训•欢迎酒会
2011年4月14日,星期四 大会报告•研讨会•研讨班
2011年4月15日,星期五 大会报告•专题讨论会•墙报•展览
2011年4月16日,星期六 专题研讨会•闭幕辞
6、会议网站
查阅更多信息,请登录“CPSA上海2011”网站:http://www.cpsa-shanghai.com
来源于:cpsa-shanghai
热门评论
最新资讯
新闻专题
更多推荐